<DOC>
	<DOC>NCT00421213</DOC>
	<brief_summary>The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.</brief_summary>
	<brief_title>Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1. Hodgkin's or nonHodgkin's Lymphoma. 2. ≥ 1 prior therapy and currently requiring therapy. 3. Evaluable disease (defined by diseasespecific criteria listed in Appendix 1) 4. ≥ 18 years of age. 5. ECOG performance score ≤ 2 (see Appendix 2). 6. Lifeexpectancy ≥ 2 months. 7. Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee with jurisdiction over the site. 8. No anticancer therapy exception of hydroxyurea ≤ 3 weeks before Baseline (Day 1, Cycle 1). 9. The following clinical laboratory values &lt; 2 weeks before Baseline: Creatinine ≤ 2X upper limit of normal (ULN). Total bilirubin ≤ 2X ULN. Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3X ULN. Exclusion Criteria 1. New York Heart Association (NYHA) functional class ≥3 myocardial infarction (see Appendix ) within 6 months before Baseline or uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc ≥450 msec; or a ≥grade2 atrioventricular (AV) block or left bundle branch block (LBBB). 2. Pregnant and/or lactating female. (Women of childbearing age must use effective contraception from Screening through the duration of study participation). 3. Uncontrolled infection. 4. Prior seizures ≥ grade3 in CTC v.3 criteria. 5. Arsenic allergy. 6. Significant neuropathology, defined as grade &gt; 2 per CTCAE Version 3.0. 7. Confusion or dementia. 8. Prior history of neurological deficits (e.g., stroke, dementia, ischemia) that has the potential to confound a postdose neurological assessment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>APL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>T-cell Lymphoma</keyword>
	<keyword>Peripheral T-cell Lymphoma</keyword>
</DOC>